Bayer Price to Book Ratio 2010-2023 | BAYRY

Historical price to book ratio values for Bayer (BAYRY) over the last 10 years. The current price to book ratio for Bayer as of May 17, 2024 is 0.74.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Bayer Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
0.00 nan
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $732.877B 105.92
Novo Nordisk (NVO) Denmark $597.021B 45.88
Johnson & Johnson (JNJ) United States $371.302B 14.75
Merck (MRK) United States $331.494B 60.31
AbbVie (ABBV) United States $290.220B 14.99
AstraZeneca (AZN) United Kingdom $238.858B 20.76
Novartis AG (NVS) Switzerland $209.898B 14.88
Pfizer (PFE) United States $163.878B 20.37
Sanofi (SNY) $123.495B 11.65
Innoviva (INVA) United States $0.998B 7.01